Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cu(II)ATSM - Procypra Therapeutics

Next Previous
X
Search
Drug Profile

Cu(II)ATSM - Procypra Therapeutics

Alternative Names: copper(II)-ATSM; Copper(II)-diacetyl-di(N4-methylthiosemicarbazone); Cu-ATSM; Cu-diacetyl-bis(N4-methylthiosemicarbazonate); diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Melbourne
  • Developer Collaborative Medicinal Development; Procypra Therapeutics
  • Class Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Phase I Parkinson's disease

Most Recent Events

  • 28 Sep 2022 Cu(II)ATSM is still in phase I trial for Parkinson's disease in Australia (Collaborative Medicinal Development pipeline, September 2022)
  • 28 Sep 2022 Cu(II)ATSM is still in phase II trials for Amyotrophic lateral sclerosis in Australia (PO) (Collaborative Medicine Development pipeline, September 2022)
  • 28 Sep 2022 No development reported - Phase-II/III for Amyotrophic lateral sclerosis in Australia (PO) (NCT04082832)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top